Hyperimmune plasma infusion in an immunocompromised Covid-19 patient previously treated for follicular lymphoma

https://doi.org/10.4081/monaldi.2021.1867

Authors

  • Guido Levi | guido.levi@yahoo.it Interventional Pulmonology Department, ASST Spedali Civili, Brescia, Italy. https://orcid.org/0000-0002-7163-2270
  • Chiara Rocchetti Interventional Pulmonology Department, ASST Spedali Civili, Brescia, Italy.
  • Roberto Magri Interventional Pulmonology Department, ASST Spedali Civili, Brescia, Italy. https://orcid.org/0000-0003-1667-2277
  • Silvia Uccelli Interventional Pulmonology Department, ASST Spedali Civili, Brescia, Italy.
  • Damiano Bottone Interventional Pulmonology Department, ASST Spedali Civili, Brescia, Italy.
  • Federico Quadri Interventional Pulmonology Department, ASST Spedali Civili, Brescia, Italy.
  • Mauro Novali Interventional Pulmonology Department, ASST Spedali Civili, Brescia, Italy.
  • Alessandro D. Santin Department of Obstetrics & Gynecology, Yale University School of Medicine, New Haven, CT, United States.
  • Michela Bezzi Interventional Pulmonology Department, ASST Spedali Civili, Brescia, Italy.

Abstract

Covid-19 in immunocompromised patients shows a prolonged course and may lead to a poor prognosis. Although data on hyperimmune plasma for treatment of Covid-19 suggest an improved outcome in immunocompetent patients, limited data are currently available in immunocompromised patients. We present the case of a 62-year-old Caucasian woman, who was previously treated with obinutuzumab and bendamustine for follicular lymphoma and showed a prolonged positive test for Covid-19. Since no improvement was observed with standard of care (including remdesivir), the possibility of hyperimmune plasma infusion was discussed. A first dose of hyperimmune plasma was administered, with subsequent onset of fever, increasing inflammatory indexes and worsening radiological findings. Three days later a second dose of plasma was administered. Within twelve hours cough and fever disappeared, and oxygen at rest was discontinued. The patient was discharged 5 days later, and nasopharyngeal swabs resulted negative 16 days after discharge.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

References

Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727-3. DOI: https://doi.org/10.1056/NEJMoa2001017

Karataş A, İnkaya AÇ, Demiroğlu H, et al. Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma. Transfus Apher Sci 2020;59:102871. DOI: https://doi.org/10.1016/j.transci.2020.102871

Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak. Cancer Discov 2020;10:783-91. DOI: https://doi.org/10.1158/2159-8290.CD-20-0422

Malsy J, Veletzky L, Heide J, et al. Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19. Clin Infect Dis 2020:ciaa1637. Online ahead of print. DOI: https://doi.org/10.1093/cid/ciaa1637

Ferrari S, Caprioli C, Weber A, et al. Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies. Leuk Lymphoma 2021;62:1490-6. DOI: https://doi.org/10.1080/10428194.2021.1872070

Shah V, Ko Ko T, Zuckerman M, et al. Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with hematological malignancies; King’s College Hospital experience. Br J Haematol 2020;190:e279-282. DOI: https://doi.org/10.1111/bjh.16935

Choi B, Choudhary MC, Regan J, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med 2020;383:2291-3. DOI: https://doi.org/10.1056/NEJMc2031364

Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - Final Report. N Engl J Med 2020;383:1813-26. DOI: https://doi.org/10.1056/NEJMc2022236

Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA 2020;117:9490–6. DOI: https://doi.org/10.1073/pnas.2006961117

Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020;323:1582-9. DOI: https://doi.org/10.1001/jama.2020.4783

Libster R, Pérez Marc G, Wappner D, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med 2021;384:610-8. DOI: https://doi.org/10.1056/NEJMoa2033700

Wright Z, Bersabe A, Eden R, et al. Successful use of COVID-19 convalescent plasma in a patient recently treated for follicular lymphoma. Clin Lymphoma Myeloma Leuk 2021;21:66-8. DOI: https://doi.org/10.1016/j.clml.2020.06.012

Downloads

Published
2021-06-10
Info
Issue
Section
COVID-19 - Collection of articles on the Coronavirus outbreak
Supporting Agencies
None
Keywords:
Covid-19, hyperimmune plasma, case report, lymphoma, cancer
Statistics
  • Abstract views: 20

  • PDF: 26
How to Cite
Levi, Guido, Chiara Rocchetti, Roberto Magri, Silvia Uccelli, Damiano Bottone, Federico Quadri, Mauro Novali, Alessandro D. Santin, and Michela Bezzi. 2021. “Hyperimmune Plasma Infusion in an Immunocompromised Covid-19 Patient Previously Treated for Follicular Lymphoma”. Monaldi Archives for Chest Disease, June. https://doi.org/10.4081/monaldi.2021.1867.

Most read articles by the same author(s)